|
|
Prepublished online as a Blood First Edition Paper on May 15, 2003; DOI 10.1182/blood-2003-01-0190.
Previous Article | Table of Contents | Next Article 
Blood, 15 September 2003, Vol. 102, No. 6, pp. 2138-2145
IMMUNOBIOLOGY
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity
Cecilia Melani,
Claudia Chiodoni,
Guido Forni, and
Mario P. Colombo
From the Immunotherapy and Gene Therapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy, and the Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
Transgenic female mice expressing the transforming rat oncogene c-erbB-2 (HER-2/neu) under the mouse mammary tumor virus (MMTV) promoter (BALB-neuT) spontaneously develop mammary carcinomas with a progression resembling that of human breast cancer. In these mice, activating antitumor immunotherapy fails to induce T cellmediated cytotoxicity, suggesting a suppression of the immune response. We found a direct correlation between tumor multiplicity and an increased proportion of Gr-1+ (Ly6G)/Mac-1+(CD11b)/ER-MP12+(CD31) immature myeloid cells in the peripheral blood (PB) and spleen, suggesting that tumor load profoundly affects overall BALB-neuT hematopoiesis. In fact, myeloid colony formation was increased in bone marrow (BM) and spleen. The immature myeloid cells displayed suppressive activity on host T lymphocytes, which progressively failed to respond to alloantigens and CD3 triggering, while maintaining the ability to proliferate in response to nonspecific mitogens. Transplantation of normal BM into BALB-neuT mice readily resulted in hypertrophic hematopoiesis with myeloid cell expansion. This persistent influence of the tumor was mediated through the release of vascular endothelial growth factor (VEGF) but not granulocyte-macrophage colony-stimulating factor (GM-CSF), and was down-modulated when tumor load was reduced but not when BM was transplanted. Together, the data obtained in the BALB-neuT model of naturally occurring carcinogenesis show that tumor-associated immune suppression is secondary to a more general alteration of host hematopoiesis, conditioned by tumor-secreted soluble factors.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. C. McKenna, K. M. Beatty, R. A. Bilonick, L. Schoenfield, K. L. Lathrop, and A. D. Singh
Activated CD11b+ CD15+ Granulocytes Increase in the Blood of Patients with Uveal Melanoma
Invest. Ophthalmol. Vis. Sci.,
September 1, 2009;
50(9):
4295 - 4303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ilkovitch and D. M. Lopez
The Liver Is a Site for Tumor-Induced Myeloid-Derived Suppressor Cell Accumulation and Immunosuppression
Cancer Res.,
July 1, 2009;
69(13):
5514 - 5521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Stewart, D. J. Liewehr, S. M. Steinberg, K. M. Greeneltch, and S. I. Abrams
Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells
J. Immunol.,
July 1, 2009;
183(1):
117 - 128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Norian, P. C. Rodriguez, L. A. O'Mara, J. Zabaleta, A. C. Ochoa, M. Cella, and P. M. Allen
Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism
Cancer Res.,
April 1, 2009;
69(7):
3086 - 3094.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Mailloux and M. R. I. Young
NK-Dependent Increases in CCL22 Secretion Selectively Recruits Regulatory T Cells to the Tumor Microenvironment
J. Immunol.,
March 1, 2009;
182(5):
2753 - 2765.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo, S. Giampaoli, A. Fridman, A. Bagchi, C. T. Winkelmann, R. Gibson, et al.
Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9
Clin. Cancer Res.,
March 1, 2009;
15(5):
1575 - 1584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kusmartsev, Z. Su, A. Heiser, J. Dannull, E. Eruslanov, H. Kubler, D. Yancey, P. Dahm, and J. Vieweg
Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
Clin. Cancer Res.,
December 15, 2008;
14(24):
8270 - 8278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Nausch, I. E. Galani, E. Schlecker, and A. Cerwenka
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells
Blood,
November 15, 2008;
112(10):
4080 - 4089.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-I. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
J. Immunol.,
October 15, 2008;
181(8):
5791 - 5802.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Re and J. L. Cook
The physiological basis of intracrine stem cell regulation
Am J Physiol Heart Circ Physiol,
August 1, 2008;
295(2):
H447 - H453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Willimsky, M. Czeh, C. Loddenkemper, J. Gellermann, K. Schmidt, P. Wust, H. Stein, and T. Blankenstein
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness
J. Exp. Med.,
July 7, 2008;
205(7):
1687 - 1700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kobayashi, T. Yoshida, D. Takeuchi, V. C. Jones, K. Shigematsu, D. N. Herndon, and F. Suzuki
Gr-1+CD11b+ cells as an accelerator of sepsis stemming from Pseudomonas aeruginosa wound infection in thermally injured mice
J. Leukoc. Biol.,
June 1, 2008;
83(6):
1354 - 1362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Movahedi, M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
Blood,
April 15, 2008;
111(8):
4233 - 4244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili
Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors
Cancer Res.,
April 1, 2008;
68(7):
2436 - 2446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wels, R. N. Kaplan, S. Rafii, and D. Lyden
Migratory neighbors and distant invaders: tumor-associated niche cells
Genes & Dev.,
March 1, 2008;
22(5):
559 - 574.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Levchenko, N. Veitonmaki, A. Lundkvist, H. Gerhardt, Y. Ming, K. Berggren, A. Kvanta, R. Carlsson, and L. Holmgren
Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo
FASEB J,
March 1, 2008;
22(3):
880 - 889.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.-Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S.-H. Chen
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
Blood,
January 1, 2008;
111(1):
219 - 228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo
Amino-Biphosphonate Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma
Cancer Res.,
December 1, 2007;
67(23):
11438 - 11446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg
Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression
Cancer Res.,
October 15, 2007;
67(20):
10019 - 10026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Talmadge
Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5243 - 5248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Celis
Toll-like Receptor Ligands Energize Peptide Vaccines through Multiple Paths
Cancer Res.,
September 1, 2007;
67(17):
7945 - 7947.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Ko, Y.-J. Kim, Y.-S. Kim, W.-S. Chang, S.-Y. Ko, S.-Y. Chang, S. Sakaguchi, and C.-Y. Kang
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
Cancer Res.,
August 1, 2007;
67(15):
7477 - 7486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Sinha, V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg
Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response
J. Immunol.,
July 15, 2007;
179(2):
977 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Spadaro, C. Curcio, A. Varadhachary, F. Cavallo, J. Engelmayer, P. Blezinger, F. Pericle, and G. Forni
Requirement for IFN-{gamma}, CD8+ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu+ Tumors
Cancer Res.,
July 1, 2007;
67(13):
6425 - 6432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yu, C. Liu, K. Su, J. Wang, Y. Liu, L. Zhang, C. Li, Y. Cong, R. Kimberly, W. E. Grizzle, et al.
Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells
J. Immunol.,
June 1, 2007;
178(11):
6867 - 6875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis
Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors
Cancer Res.,
February 1, 2007;
67(3):
1326 - 1334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G Parmiani, C Castelli, L Pilla, M Santinami, M. Colombo, and L Rivoltini
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Ann. Onc.,
February 1, 2007;
18(2):
226 - 232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Rolla, C. Nicolo, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria
Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice
J. Immunol.,
December 1, 2006;
177(11):
7626 - 7633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Chiodoni, M. Iezzi, C. Guiducci, S. Sangaletti, I. Alessandrini, C. Ratti, F. Tiboni, P. Musiani, D. N. Granger, and M. P. Colombo
Triggering CD40 on endothelial cells contributes to tumor growth
J. Exp. Med.,
October 30, 2006;
203(11):
2441 - 2450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich
All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients.
Cancer Res.,
September 15, 2006;
66(18):
9299 - 9307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ambrosino, M. Spadaro, M. Iezzi, C. Curcio, G. Forni, P. Musiani, W.-Z. Wei, and F. Cavallo
Immunosurveillance of erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.
Cancer Res.,
August 1, 2006;
66(15):
7734 - 7740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Van Ginderachter, S. Meerschaut, Y. Liu, L. Brys, K. De Groeve, G. Hassanzadeh Ghassabeh, G. Raes, and P. De Baetselier
Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer
Blood,
July 15, 2006;
108(2):
525 - 535.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Yang, Z. Cai, Y. Zhang, W. H. Yutzy IV, K. F. Roby, and R. B.S. Roden
CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells.
Cancer Res.,
July 1, 2006;
66(13):
6807 - 6815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Song, Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte
CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1{beta}-Secreting Cells
J. Immunol.,
December 15, 2005;
175(12):
8200 - 8208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kusmartsev, S. Nagaraj, and D. I. Gabrilovich
Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells
J. Immunol.,
October 1, 2005;
175(7):
4583 - 4592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Larrivee, I. Pollet, and A. Karsan
Activation of Vascular Endothelial Growth Factor Receptor-2 in Bone Marrow Leads to Accumulation of Myeloid Cells: Role of Granulocyte-Macrophage Colony-Stimulating Factor
J. Immunol.,
September 1, 2005;
175(5):
3015 - 3024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kusmartsev and D. I. Gabrilovich
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
J. Immunol.,
April 15, 2005;
174(8):
4880 - 4891.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Zehntner, C. Brickman, L. Bourbonniere, L. Remington, M. Caruso, and T. Owens
Neutrophils That Infiltrate the Central Nervous System Regulate T Cell Responses
J. Immunol.,
April 15, 2005;
174(8):
5124 - 5131.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. De Santo, P. Serafini, I. Marigo, L. Dolcetti, M. Bolla, P. Del Soldato, C. Melani, C. Guiducci, M. P. Colombo, M. Iezzi, et al.
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination
PNAS,
March 15, 2005;
102(11):
4185 - 4190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Serafini, R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello
High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells
Cancer Res.,
September 1, 2004;
64(17):
6337 - 6343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Dring, F. E. Davies, J. A. L. Fenton, P. L. Roddam, K. Scott, D. Gonzalez, S. Rollinson, A. C. Rawstron, K. S. Rees-Unwin, C. Li, et al.
A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma
Clin. Cancer Res.,
September 1, 2004;
10(17):
5692 - 5701.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|